In addition to the global #1 ranking in biosimilars1 and generic antibiotics2, dermatology2 and transplantation medicines2, Sandoz portfolio of products in Canada includes six biosimilars and over 700 generic products3 covering 280 molecules and medicinal ingredients spanning multiple therapeutic areas including:
Central nervous system (CNS)
Our broad portfolio encompasses a range of formulations and devices, including injectables, multiple-unit tablets, capsules, creams and gels, transdermal patches, and lyophilized products.
Our medicines are sold in pharmacies and used in hospitals. In 2019, Sandoz was the main provider of generic injectable medications4 to Canadian hospitals.
We are proud to play an essential role in the Canadian health care system. In 2019, Sandoz products were prescribed over 65 million times5 in Canada.
A trusted partner of healthcare professionals, Sandoz Canada has a network of suppliers that stand out for their reliability and high-quality standards. Our dedicated sales force is distinguished by the strong business relationships it has with customers and the excellent service it provides. Our broad product line falls into two categories: Generic medicines and Biosimilars.
In the combined regions of North America, Europe, Japan and Australia.
#1 In the generics market by volume.
Addition of products with a DIN and NPN - Health Canada's Drug Product Database (Sandoz query) and Health Canada's Licensed Natural Health Products Database
Internally extrapolated market share (33%) based on IMS data (total injectable sales in hospitals by manufacturer) as of February 2019 for the last 12 months.
Overview of Canadian Generic Prescription Drug Market, CGPA, as of September 2019 MAT.